NO970264L - Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein - Google Patents

Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein

Info

Publication number
NO970264L
NO970264L NO970264A NO970264A NO970264L NO 970264 L NO970264 L NO 970264L NO 970264 A NO970264 A NO 970264A NO 970264 A NO970264 A NO 970264A NO 970264 L NO970264 L NO 970264L
Authority
NO
Norway
Prior art keywords
binding protein
pharmaceutical compositions
chimeric tnf
tnf
chimeric
Prior art date
Application number
NO970264A
Other languages
English (en)
Other versions
NO970264D0 (no
Inventor
Robert Frederick Geoffre Booth
Werner Lesslauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO970264D0 publication Critical patent/NO970264D0/no
Publication of NO970264L publication Critical patent/NO970264L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Foreliggende oppfinnelse er rettet mot anvendelse av et chimærisk TNF-bindende protein som omfatter en oppløselig del av den humane p55- eller p-75- TNF-reseptor og alt eller deler av de konstante domener av den tunge eller lette kjede av humant immunoglobulin eller et farmasøytisk akseptabelt salt derav for fremstilling av en farmasøytisk sammensetning for behandling av autoimmune sykdommer.
NO970264A 1994-07-22 1997-01-21 Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein NO970264L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94111455 1994-07-22
PCT/EP1995/002788 WO1996003141A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Publications (2)

Publication Number Publication Date
NO970264D0 NO970264D0 (no) 1997-01-21
NO970264L true NO970264L (no) 1997-03-24

Family

ID=8216138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970264A NO970264L (no) 1994-07-22 1997-01-21 Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein

Country Status (11)

Country Link
EP (1) EP0772449A1 (no)
JP (1) JPH09508140A (no)
AU (1) AU3111995A (no)
BR (1) BR9508419A (no)
CA (1) CA2195665A1 (no)
CZ (1) CZ283219B6 (no)
FI (1) FI970247A (no)
HU (1) HUT76666A (no)
NO (1) NO970264L (no)
PL (1) PL318501A1 (no)
WO (1) WO1996003141A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
JP2001526632A (ja) * 1996-12-12 2001-12-18 ジェネンテク，インコーポレイテッド Ｈｖｅｍポリペプチドとその用途
JP2002531902A (ja) 1998-11-27 2002-09-24 シナプティックス （ユーケー）リミテッド 位置センサ
SK10472003A3 (sk) 2001-02-23 2004-03-02 Immunex Corporation Zvýšený výťažok aktívnych proteínov
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
SI1471974T1 (sl) 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
DK0939121T4 (da) * 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
JPH08509203A (ja) * 1992-10-15 1996-10-01 ダナ−ファーバー キャンサー インステテュート インコーポレイテッド ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療

Also Published As

Publication number Publication date
EP0772449A1 (en) 1997-05-14
JPH09508140A (ja) 1997-08-19
FI970247A0 (fi) 1997-01-21
AU3111995A (en) 1996-02-22
CA2195665A1 (en) 1996-02-08
WO1996003141A1 (en) 1996-02-08
CZ283219B6 (cs) 1998-02-18
PL318501A1 (en) 1997-06-23
NO970264D0 (no) 1997-01-21
BR9508419A (pt) 1997-11-18
FI970247A (fi) 1997-01-21
CZ19397A3 (en) 1997-06-11
HUT76666A (en) 1997-10-28

Similar Documents

Publication Publication Date Title
NO970264L (no) Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein
DE69028671D1 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
ATE305798T1 (de) Anti-tnf antikörper / tnf rezeptor und methotrexat zur behandlung von autoimmunkrankheiten
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE3854741T3 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
AU4741997A (en) Oral administration of chicken yolk antibodies to treat disease
IT8248200A0 (it) Preparato farmaceutico per la cura del diabete mellitus
ES2133329T3 (es) Variantes de il-3 humana.
DE58902712D1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
NZ335353A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
KR900011717A (ko) 페닐히드라존, 이들의 제조방법 및 이들로부터 제조된 치료 및 미용 조성물
IT9020968A0 (it) Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche
IT8026233A0 (it) Derivato della n-acetil-cisteina ad attivita' terapeutica, procedimento per la sua preparazione e relative composizioni farmaceutiche.
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DK452788D0 (da) Smertestillende praeparat
BR8804939A (pt) Composicao de poliolefinas com carga de negro de fumo estabilizadas
IT8324141A0 (it) Preparato per la cura delle ustioni.
NO923078D0 (no) Skumbar sammensetning for farmasoeytisk anvendelse, anvendelse derav og fremgangsmaate for behandling
FR2699174B1 (fr) Dérivés de 3-(quinoléin-6-yl-méthyl)-4H-imidazol-4-one, leur préparation et leur application en thérapeutique.
ATE211914T1 (de) Wismuth enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
DK102488D0 (da) Praeparat til behandling af tandsygdomme